Cultured circulating tumor cells and their derived xenografts for personalized oncology
Ruoxiang Wang(Cedars-Sinai Medical Center), Leland W. K. Chung(Cedars-Sinai Medical Center), Edwin M. Posadas(Cedars-Sinai Medical Center), Nallasivam Palanisamy(Henry Ford Health System), Stephen J. Pandol(Cedars-Sinai Medical Center), Hsian‐Rong Tseng(California NanoSystems Institute), Michael R. Freeman(Cedars-Sinai Medical Center), Michael Lewis, James S. Tomlinson(Imperial College Healthcare NHS Trust), Alagappan Annamalai(Cedars-Sinai Medical Center), Gina Chia‐Yi Chu(Multimeric Biotherapeutics (United States)), Nicholas N. Nissen(Cedars-Sinai Medical Center), Stefan Mrđenović(Cedars-Sinai Medical Center), Haiyen E. Zhau(Cedars-Sinai Medical Center), Andrew Hendifar(Cedars-Sinai Medical Center)
Cited by 41
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
A 160-kilobit molecular electronic memory patterned at 1011 bits per square centimetre
|Nature|2007|1.2k
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
|PubMed|1994|739
The pancreatic stellate cell: a star on the rise in pancreatic diseases
|Journal of Clinical Investigation|2007|686
Linear Artificial Molecular Muscles
|Journal of the American Chemical Society|2005|664